The FINANCIAL — Gilead Sciences, Inc. and Novo Nordisk A/S announced results from a phase 2 proof-of-concept trial. The five-arm trial evaluated combinations of Novo Nordisk’s semaglutide, a GLP-1 receptor agonist, with Gilead’s investigational FXR agonist cilofexor and/or Gilead’s investigational ACC inhibitor firsocostat over 24 weeks in 108 people with non-alcoholic steatohepatitis (NASH). The results were presented at The Liver Meeting Digital Experience (TLMdX), 13–16 November 2020 (Late Breaker #L02). The trial met its primary endpoint by demonstrating that in people with NASH and mild to moderate fibrosis all regimens were well tolerated. The most common adverse events (AEs) were…
Read More »
The FINANCIAL — Gilead Sciences, Inc. and Novo Nordisk A/S announced results from a phase 2 proof-of-concept trial. The five-arm trial evaluated combinations of Novo Nordisk’s semaglutide, a GLP-1 receptor agonist, with Gilead’s investigational FXR agonist cilofexor and/or Gilead’s investigational ACC inhibitor firsocostat over 24 weeks in 108 people with non-alcoholic steatohepatitis (NASH). The results…
You might be interested in
The FINANCIAL — For the eleventh time, Roche has been recognised as the most sustainable company in the Pharmaceuticals index…
The FINANCIAL — Metagenomi, a next generation gene editing company launched by UC Berkeley scientists in 2018, successfully completed a…
The FINANCIAL — On the occasion of the World Health Assembly, the world’s research-based and generic & biosimilar pharmaceutical industry bodies…
The FINANCIAL – Novo Nordisk published financial report for the period 1 January 2020 to 30 September 2020 Sales increased by 6% in Danish kroner and by 7% at CER to DKK 94.8 billion. Sales in International Operations increased by 9% in Danish kroner (12% at CER), and sales in North America Operations increased by…
You might be interested in
The FINANCIAL — For the eleventh time, Roche has been recognised as the most sustainable company in the Pharmaceuticals index…
The FINANCIAL — Gilead Sciences, Inc. and Novo Nordisk A/S announced results from a phase 2 proof-of-concept trial. The five-arm…
The FINANCIAL — Metagenomi, a next generation gene editing company launched by UC Berkeley scientists in 2018, successfully completed a…